CompletedNCT00471354

A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine

Medication studyAges 8–11Multiple countriesADHD

The study in practice

Understand this study

Listed age limits: 8 years to 11 years.

Listed locations: Beijing and 7 more locationsSee all locations and recruitment
Study phase: Phase 4

Study clarity

Study start dateApril 2007

Recruitment status: Completed
Enrollment listed in the registry: 228
Sponsor: Eli Lilly and Company
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: China, South Korea, Taiwan
Age range: From 8 Years to 11 Years
Official registry ID: NCT00471354
Official title: Show the full official title
Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride

Completed

Beijing, China · Shanghai, China · Pusan, South Korea

5 more locations

FAQ

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine.

Who was this study for?

Listed age limits: 8 years to 11 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.